Divine Aleru, Microbiome Medicine Research Coordinator

Traditionally linked to genetic predispositions and environmental exposures, emerging evidence highlights the microbiome as a critical and underappreciated factor influencing breast cancer progression, immune response, and treatment outcomes.

Pelvic Inflammatory Disease (PID) is a complex interplay between pathogens, immune responses, and microbial communities. As research continues to uncover the microbiome’s role in reproductive health, microbiome-targeted interventions (MBTIs) such as probiotics, prebiotics, and transplants are redefining how we prevent and treat PID. This page dives deep into these innovations, offering a glimpse into the future of personalized, biologically informed women’s healthcare.

Postpartum depression (PPD) affects many new mothers, influencing emotional, mental, and physical well-being. The gut microbiome, hormones, diet, and exercise all play a significant role in the onset, severity, and management of PPD. Early intervention, including probiotics, dietary changes, and therapy, can effectively alleviate symptoms and improve maternal and child health outcomes.

Premenstrual Syndrome (PMS) involves physical and emotional symptoms linked to hormonal fluctuations. Recent research highlights the role of heavy metals and gut microbiome imbalances in worsening these symptoms. Lifestyle changes, microbiome-targeted therapies, and toxin reduction show promise in effective PMS management.

Routine consumption of hibiscus tea or juice may affect female fertility by disrupting ovulation, implantation, and hormonal balance. Women trying to conceive or undergoing fertility treatments should be cautious and discuss herbal intake with their healthcare provider to avoid unintended reproductive consequences.

Colibactin is a microbiome-derived genotoxin produced by a subset of gut-associated bacteria that carry the pks (clb) biosynthetic gene cluster. Rather than acting like a classical acute toxin, colibactin is clinically relevant because it can chemically damage host DNA, creating lesions that are difficult to repair and that may leave persistent mutations if cells survive. In a microbiome systems context, colibactin is best understood as a functional output of specific bacterial metabolism that can intersect with host genome stability, particularly at the intestinal epithelial interface.

This study shows a selective small molecule can block colibactin production by inhibiting the activating enzyme ClbP. The inhibitor stops colibactin-linked DNA damage signals and DNA adduct formation in infected cells and remains effective in a fecal microbiome model without broad antibiotic effects.

This review explains how gut microbiota can guide cancer screening and treatment, focusing on colibactin-producing E. coli in colorectal cancer. It links pks-positive E. coli to DNA damage, mutational fingerprints, senescence, and immune changes, and it outlines ways to target colibactin activity.

This addendum explains how colibactin-producing E. coli can speed colon tumor growth by inducing senescence and a growth-factor secretory program. The pathway runs through c-Myc, miR-20a-5p, SENP1, and altered p53 SUMOylation, with HGF signaling driving proliferation of nearby uninfected tumor cells.

This study performed a meta-analysis to clarify whether carrying colibactin-producing pks+ Escherichia coli associates with a higher risk of colorectal cancer (CRC), because prior individual studies reported conflicting results. The authors systematically searched major databases up to October 18, 2021, extracted case–control and cohort data where CRC status was confirmed and pks […]

his study shows colibactin-producing bacteria directly create DNA interstrand cross-links in human cells, triggering ATR replication stress and Fanconi repair responses. Blocking colibactin maturation or adding ClbS prevents cross-links, and inhibiting ATR or FANCD2 lowers cell survival, defining ICLs as the key lesion.

This study shows colibactin harms bacteria, triggers DNA damage defenses, and leaves a bacteria-specific mutation signature. Colibactin kills neighboring E. coli under contact-rich conditions, induces A/T-motif mutations (often T→A), and even causes self-damage in pks+ producers despite resistance.

This study used structural biology to define how ClbK, a PKS–NRPS hybrid “megaenzyme” encoded by the pks biosynthetic gene cluster in colibactin-producing Enterobacteriaceae, is built and how its architecture could support a key elongation step in colibactin assembly. The authors focused on the complete trans-AT PKS module of ClbK and the full-length […]

This review explains how colibactin damages host DNA and also triggers bacterial SOS responses and prophage induction, reshaping gut communities and virulence. It connects barrier loss and inflammation to higher genotoxic risk and frames colibactin genes as functional microbiome biomarkers.

This mini-review explains how pks-positive E. coli make colibactin and how it drives colorectal cancer through DNA crosslinks, double-strand breaks, and mutational signatures such as SBS and ID-pks. It also summarizes key toxin-maturation steps that may enable targeted prevention.

This review explains how pks+ E. coli control colibactin production and why iron, oxygen, inflammation, diet, and drugs change DNA damage risk. It highlights ClbR regulation, inflammation-linked clb upregulation, and interventions such as mesalamine, d-serine, and SCFAs that can reduce genotoxicity.

This study found that many SPF laboratory rats carry phylogroup B2 E. coli with genotoxins, especially the pks colibactin island, and that vendor source strongly affects prevalence. These strains cause toxin-typical cytopathic effects and may confound rat models of infection, inflammation, and cancer.

This review explains how pks-positive bacteria produce colibactin, how it damages host DNA, and why it links to colorectal cancer and invasive infection severity. It also summarizes toxin-pathway inhibition as a prevention strategy while noting pks-derived anti-inflammatory and analgesic effects.

The human microbiome plays a critical role in metal metabolism, influencing both metal absorption and the potential for mismetallation in the body. Studies show that heavy metals can disrupt microbial diversity, leading to dysbiosis and altered metabolic functions in the gut. Moreover, some microbes possess the ability to sequester toxic metals, preventing their absorption and thus minimizing the risks of mismetallation in host tissues. As research in this area progresses, understanding these microbiota-metal interactions will be crucial for exploring new avenues in the prevention and treatment of metal-associated diseases.

This review focuses on the role of probiotics, specifically lactobacilli, in bioremediation and the detoxification of heavy metals. The paper reviews how microbial processes, especially those of gastrointestinal bacteria, interact with heavy metals like arsenic, cadmium, mercury, and lead. It emphasizes the potential of probiotics in removing or sequestering these metals from […]

This review examines how metal(loid) exposure affects gut microbiota composition and function. It also evaluates microbiota-related strategies for metal(loid) detoxification.

This study explores the essential role of metal ions in human health, detailing their involvement in enzyme catalysis and the impacts of imbalances on diseases. It also highlights potential clinical applications for metal-based therapies.

This review examines bacterial metallostasis, focusing on metal sensing, metalloproteome remodeling, and metal trafficking. It highlights key regulatory mechanisms and implications for therapeutic interventions and synthetic biology.

This review examines the role of metallochaperones in copper and nickel ion transport, highlighting their significance in metal ion homeostasis and implications for treating diseases like Wilson’s and Menkes diseases.